Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 250

1.

Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate.

Chakrabarti BK, Ling X, Yang ZY, Montefiori DC, Panet A, Kong WP, Welcher B, Louder MK, Mascola JR, Nabel GJ.

Vaccine. 2005 May 16;23(26):3434-45.

PMID:
15837367
[PubMed - indexed for MEDLINE]
2.

Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.

Kim M, Qiao ZS, Montefiori DC, Haynes BF, Reinherz EL, Liao HX.

AIDS Res Hum Retroviruses. 2005 Jan;21(1):58-67.

PMID:
15665645
[PubMed - indexed for MEDLINE]
4.

Cross-clade recognition and neutralization by the V3 region from clade C human immunodeficiency virus-1 envelope.

Wu L, Yang ZY, Xu L, Welcher B, Winfrey S, Shao Y, Mascola JR, Nabel GJ.

Vaccine. 2006 Jun 5;24(23):4995-5002. Epub 2006 Apr 18.

PMID:
16690178
[PubMed - indexed for MEDLINE]
5.

The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.

Barnett SW, Lu S, Srivastava I, Cherpelis S, Gettie A, Blanchard J, Wang S, Mboudjeka I, Leung L, Lian Y, Fong A, Buckner C, Ly A, Hilt S, Ulmer J, Wild CT, Mascola JR, Stamatatos L.

J Virol. 2001 Jun;75(12):5526-40.

PMID:
11356960
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins.

Mascola JR, Sambor A, Beaudry K, Santra S, Welcher B, Louder MK, Vancott TC, Huang Y, Chakrabarti BK, Kong WP, Yang ZY, Xu L, Montefiori DC, Nabel GJ, Letvin NL.

J Virol. 2005 Jan;79(2):771-9.

PMID:
15613305
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multi-clade HIV-1 envelope immunogens.

Seaman MS, Leblanc DF, Grandpre LE, Bartman MT, Montefiori DC, Letvin NL, Mascola JR.

Virology. 2007 Oct 10;367(1):175-86. Epub 2007 Jun 27.

PMID:
17599382
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB, Schwartz DH, Clements ML, Dolin R, Graham BS, Gorse GJ, Keefer MC, McElrath MJ, Walker MC, Wagner KF, McNeil JG, McCutchan FE, Burke DS.

J Infect Dis. 1996 Feb;173(2):340-8.

PMID:
8568294
[PubMed - indexed for MEDLINE]
Free Article
9.

Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa.

Bures R, Morris L, Williamson C, Ramjee G, Deers M, Fiscus SA, Abdool-Karim S, Montefiori DC.

J Virol. 2002 Mar;76(5):2233-44.

PMID:
11836401
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E.

Wang S, Pal R, Mascola JR, Chou TH, Mboudjeka I, Shen S, Liu Q, Whitney S, Keen T, Nair BC, Kalyanaraman VS, Markham P, Lu S.

Virology. 2006 Jun 20;350(1):34-47. Epub 2006 Apr 17.

PMID:
16616287
[PubMed - indexed for MEDLINE]
Free Article
11.

Characterization of neutralizing antibody responses elicited by clade A envelope immunogens derived from early transmitted viruses.

Kraft Z, Strouss K, Sutton WF, Cleveland B, Tso FY, Polacino P, Overbaugh J, Hu SL, Stamatatos L.

J Virol. 2008 Jun;82(12):5912-21. doi: 10.1128/JVI.00389-08. Epub 2008 Apr 9.

PMID:
18400850
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12.

Mascola JR, Louder MK, VanCott TC, Sapan CV, Lambert JS, Muenz LR, Bunow B, Birx DL, Robb ML.

J Virol. 1997 Oct;71(10):7198-206.

PMID:
9311792
[PubMed - indexed for MEDLINE]
Free PMC Article
13.
14.

Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope.

VanCott TC, Mascola JR, Loomis-Price LD, Sinangil F, Zitomersky N, McNeil J, Robb ML, Birx DL, Barnett S.

J Virol. 1999 Jun;73(6):4640-50.

PMID:
10233923
[PubMed - indexed for MEDLINE]
Free PMC Article
15.
16.

Study of the V3 loop as a target epitope for antibodies involved in the neutralization of primary isolates versus T-cell-line-adapted strains of human immunodeficiency virus type 1.

Spenlehauer C, Saragosti S, Fleury HJ, Kirn A, Aubertin AM, Moog C.

J Virol. 1998 Dec;72(12):9855-64.

PMID:
9811721
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1.

Zolla-Pazner S, Zhong P, Revesz K, Volsky B, Williams C, Nyambi P, Gorny MK.

AIDS Res Hum Retroviruses. 2004 Nov;20(11):1254-8.

PMID:
15588347
[PubMed - indexed for MEDLINE]
18.

Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain.

Lian Y, Srivastava I, Gómez-Román VR, Zur Megede J, Sun Y, Kan E, Hilt S, Engelbrecht S, Himathongkham S, Luciw PA, Otten G, Ulmer JB, Donnelly JJ, Rabussay D, Montefiori D, van Rensburg EJ, Barnett SW.

J Virol. 2005 Nov;79(21):13338-49.

PMID:
16227256
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Immunogenicity of recombinant envelope glycoproteins derived from T-cell line-adapted isolates or primary HIV isolates: a comparative study using multivalent vaccine approaches.

Lemiale F, Brand D, Lebigot S, Verrier B, Buzelay L, Brunet S, Barin F.

J Acquir Immune Defic Syndr. 2001 Apr 15;26(5):413-22.

PMID:
11391160
[PubMed - indexed for MEDLINE]
20.

High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination.

Davis KL, Gray ES, Moore PL, Decker JM, Salomon A, Montefiori DC, Graham BS, Keefer MC, Pinter A, Morris L, Hahn BH, Shaw GM.

Virology. 2009 May 10;387(2):414-26. doi: 10.1016/j.virol.2009.02.022. Epub 2009 Mar 18.

PMID:
19298995
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk